Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
Novo Nordisk A/S, the world’s largest insulin maker, raised its full year sales and profit forecasts after reporting second-quarter earnings that beat analysts’ estimates. The shares rose to a record.
On Air Now
In The Loop with Betty Liu
©2014 Bloomberg L.P. All Rights Reserved. Made in NYC